The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis

The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We compared survival, local recurrence of metastasis detected by imaging, the disease-free interval, relapses of neurological deterioration, and the ability to walk between groups. Molecularly targeted drugs were administered to 39 patients after surgery (TT group) and were not administered to 125 patients (non-TT group). Median survival was significantly longer in the TT group (1027 days) than in the non-TT group (439 days, p < 0.01). Local recurrence occurred in 25 patients in the non-TT group and 10 patients in the TT group. The disease-free interval did not differ between groups. Neurological deterioration was observed in three patients in the non-TT group and no patients in the TT group. The ability to walk was preserved in 97.6% of patients in the TT group and 88% of patients in the non-TT group (p = 0.12). In conclusion, molecularly targeted drugs improve survival in patients with spinal metastasis but do not alter local control of metastatic tumors.

Automated summary

The study aimed to investigate the effects of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants were divided into two groups, one receiving targeted therapy after surgery (TT group) and the other not receiving targeted therapy (non-TT group). The results showed that the TT group had significantly longer median survival, less local recurrence, and better preservation of neurological function and ability to walk compared to the non-TT group. In conclusion, molecularly targeted drugs improve survival but do not alter local control of metastatic tumors in patients with spinal metastasis.